Pharming Group NV Total Assets
Pharming Group NV total assets. Based on the latest financial reports, Pharming Group NV (PHARM) holds total assets worth €473.79 Million EUR (≈ $553.90 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Pharming Group NV stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Pharming Group NV (2005–2024)
Total assets of Pharming Group NV from 2005 to 2024. This chart illustrates how Pharming Group NV's total assets have evolved over time, based on quarterly financial data. See today's stock price for Pharming Group NV for real-time trading data and today's change.
Pharming Group NV - Asset Composition Analysis
Pharming Group NV Total Assets Breakdown (December 2024)
Pharming Group NV total assets breakdown as of December 2024. Pharming Group NV's total assets of €473.79 Million consist of 69.5% current assets and 30.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.7% |
| Accounts Receivable | €48.45 Million | 12.5% |
| Inventory | €53.81 Million | 13.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €58.95 Million | 15.2% |
| Goodwill | €-25.46K | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Pharming Group NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Pharming Group NV's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharming Group NV's current assets represent 69.5% of total assets in 2024, a decrease from 73.8% in 2005.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2024, down from 42.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 11.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 15.2% of total assets.
Pharming Group NV Competitors by Total Assets
Key competitors of Pharming Group NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Pharming Group NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.16 | 3.53 | 3.43 |
| Quick Ratio | 2.39 | 2.76 | 3.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €189.69 Million | €202.35 Million | €186.66 Million |
Pharming Group NV - Advanced Valuation Insights
This section examines the relationship between Pharming Group NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.16 |
| Latest Market Cap to Assets Ratio | 2.32 |
| Asset Growth Rate (YoY) | -9.3% |
| Total Assets | €386.88 Million |
| Market Capitalization | $897.17 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Pharming Group NV's assets at a significant premium (2.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Pharming Group NV's assets decreased by 9.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharming Group NV (2005–2024)
The table below shows the annual total assets of Pharming Group NV from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €386.88 Million ≈ $452.30 Million |
-9.26% |
| 2023-12-31 | €426.34 Million ≈ $498.44 Million |
+0.13% |
| 2022-12-31 | €425.80 Million ≈ $497.80 Million |
+7.28% |
| 2021-12-31 | €396.90 Million ≈ $464.02 Million |
-5.30% |
| 2020-12-31 | €419.12 Million ≈ $489.99 Million |
+63.95% |
| 2019-12-31 | €255.63 Million ≈ $298.86 Million |
+4.15% |
| 2018-12-31 | €245.45 Million ≈ $286.95 Million |
+23.11% |
| 2017-12-31 | €199.38 Million ≈ $233.09 Million |
+49.53% |
| 2016-12-31 | €133.34 Million ≈ $155.89 Million |
+111.45% |
| 2015-12-31 | €63.06 Million ≈ $73.72 Million |
-6.93% |
| 2014-12-31 | €67.75 Million ≈ $79.21 Million |
+56.22% |
| 2013-12-31 | €43.37 Million ≈ $50.70 Million |
+94.69% |
| 2012-12-31 | €22.28 Million ≈ $26.04 Million |
-30.40% |
| 2011-12-31 | €32.01 Million ≈ $37.42 Million |
-35.46% |
| 2010-12-31 | €49.59 Million ≈ $57.98 Million |
-38.06% |
| 2009-12-31 | €80.07 Million ≈ $93.61 Million |
-14.28% |
| 2008-12-31 | €93.40 Million ≈ $109.20 Million |
-43.98% |
| 2007-12-31 | €166.72 Million ≈ $194.91 Million |
+59.74% |
| 2006-12-31 | €104.37 Million ≈ $122.02 Million |
+154.78% |
| 2005-12-31 | €40.96 Million ≈ $47.89 Million |
-- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more